The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in Radiation Therapy Oncology Group prospective trials 0116 and 0128

Akila Viswanathan, Jennifer Moughan, William Small, Charles Levenback, Revathy Iyer, Sharon Hymes, Adam P. Dicker, Brigitte Miller, Beth Erickson, David K. Gaffney

Research output: Contribution to journalArticle

Abstract

Purpose: The objective of the study was to determine the impact of brachytherapy implant quality on outcome among cervical cancer patients treated on Radiation Therapy Oncology Group prospective trials 0116 and 0128. Methods: All enrolled patients received concurrent chemoradiation followed by brachytherapy. Individual brachytherapy parameters, including the symmetry of ovoids in relation to the tandem, displacement of ovoids in relation to the cervical os, tandem bisecting the ovoids, tandem in the midpelvis, and appropriateness of packing, were scored for each implant. Multivariate Cox proportional hazards models were constructed for each parameter for local recurrence (LR), regional recurrence, distant recurrence, disease-free survival (DFS), and overall survival. Results: Records for 103 patients were analyzed. The median follow-up time was 24.5 months. Patients with unacceptable symmetry of ovoids to the tandem had a significantly higher risk of LR than patients in the acceptable group (hazard ratio [HR], 2.67; 95% confidence interval [CI], 1.11-6.45; P = 0.03). Patients with displacement of ovoids in relation to the cervical os had a significantly increased risk of LR (HR, 2.50; 95% CI, 1.05-5.93; P = 0.04) and a lower DFS rate (HR, 2.28; 95% CI, 1.18-4.41; P = 0.01). Inappropriate placement of packing resulted in a lower DFS rate (HR, 2.06; 95% CI, 1.08-3.92; P = 0.03). Conclusions: Assessment of the quality of a brachytherapy implant is imperative, as proper placement has an impact on patient DFS. If feasible, inappropriate placements should be corrected before treatment initiation. Brachytherapy applicators for cervical cancer should preferably be placed and assessed by experienced practitioners.

Original languageEnglish (US)
Pages (from-to)123-131
Number of pages9
JournalInternational Journal of Gynecological Cancer
Volume22
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Radiation Oncology
Brachytherapy
Uterine Cervical Neoplasms
Disease-Free Survival
Radiotherapy
Recurrence
Confidence Intervals
Survival Rate
Proportional Hazards Models
Survival

Keywords

  • Brachytherapy quality
  • Cervical cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in Radiation Therapy Oncology Group prospective trials 0116 and 0128. / Viswanathan, Akila; Moughan, Jennifer; Small, William; Levenback, Charles; Iyer, Revathy; Hymes, Sharon; Dicker, Adam P.; Miller, Brigitte; Erickson, Beth; Gaffney, David K.

In: International Journal of Gynecological Cancer, Vol. 22, No. 1, 01.2012, p. 123-131.

Research output: Contribution to journalArticle

Viswanathan, Akila ; Moughan, Jennifer ; Small, William ; Levenback, Charles ; Iyer, Revathy ; Hymes, Sharon ; Dicker, Adam P. ; Miller, Brigitte ; Erickson, Beth ; Gaffney, David K. / The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in Radiation Therapy Oncology Group prospective trials 0116 and 0128. In: International Journal of Gynecological Cancer. 2012 ; Vol. 22, No. 1. pp. 123-131.
@article{12f6421ffac84eddaacf5e50438963e2,
title = "The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in Radiation Therapy Oncology Group prospective trials 0116 and 0128",
abstract = "Purpose: The objective of the study was to determine the impact of brachytherapy implant quality on outcome among cervical cancer patients treated on Radiation Therapy Oncology Group prospective trials 0116 and 0128. Methods: All enrolled patients received concurrent chemoradiation followed by brachytherapy. Individual brachytherapy parameters, including the symmetry of ovoids in relation to the tandem, displacement of ovoids in relation to the cervical os, tandem bisecting the ovoids, tandem in the midpelvis, and appropriateness of packing, were scored for each implant. Multivariate Cox proportional hazards models were constructed for each parameter for local recurrence (LR), regional recurrence, distant recurrence, disease-free survival (DFS), and overall survival. Results: Records for 103 patients were analyzed. The median follow-up time was 24.5 months. Patients with unacceptable symmetry of ovoids to the tandem had a significantly higher risk of LR than patients in the acceptable group (hazard ratio [HR], 2.67; 95{\%} confidence interval [CI], 1.11-6.45; P = 0.03). Patients with displacement of ovoids in relation to the cervical os had a significantly increased risk of LR (HR, 2.50; 95{\%} CI, 1.05-5.93; P = 0.04) and a lower DFS rate (HR, 2.28; 95{\%} CI, 1.18-4.41; P = 0.01). Inappropriate placement of packing resulted in a lower DFS rate (HR, 2.06; 95{\%} CI, 1.08-3.92; P = 0.03). Conclusions: Assessment of the quality of a brachytherapy implant is imperative, as proper placement has an impact on patient DFS. If feasible, inappropriate placements should be corrected before treatment initiation. Brachytherapy applicators for cervical cancer should preferably be placed and assessed by experienced practitioners.",
keywords = "Brachytherapy quality, Cervical cancer",
author = "Akila Viswanathan and Jennifer Moughan and William Small and Charles Levenback and Revathy Iyer and Sharon Hymes and Dicker, {Adam P.} and Brigitte Miller and Beth Erickson and Gaffney, {David K.}",
year = "2012",
month = "1",
doi = "10.1097/IGC.0b013e31823ae3c9",
language = "English (US)",
volume = "22",
pages = "123--131",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in Radiation Therapy Oncology Group prospective trials 0116 and 0128

AU - Viswanathan, Akila

AU - Moughan, Jennifer

AU - Small, William

AU - Levenback, Charles

AU - Iyer, Revathy

AU - Hymes, Sharon

AU - Dicker, Adam P.

AU - Miller, Brigitte

AU - Erickson, Beth

AU - Gaffney, David K.

PY - 2012/1

Y1 - 2012/1

N2 - Purpose: The objective of the study was to determine the impact of brachytherapy implant quality on outcome among cervical cancer patients treated on Radiation Therapy Oncology Group prospective trials 0116 and 0128. Methods: All enrolled patients received concurrent chemoradiation followed by brachytherapy. Individual brachytherapy parameters, including the symmetry of ovoids in relation to the tandem, displacement of ovoids in relation to the cervical os, tandem bisecting the ovoids, tandem in the midpelvis, and appropriateness of packing, were scored for each implant. Multivariate Cox proportional hazards models were constructed for each parameter for local recurrence (LR), regional recurrence, distant recurrence, disease-free survival (DFS), and overall survival. Results: Records for 103 patients were analyzed. The median follow-up time was 24.5 months. Patients with unacceptable symmetry of ovoids to the tandem had a significantly higher risk of LR than patients in the acceptable group (hazard ratio [HR], 2.67; 95% confidence interval [CI], 1.11-6.45; P = 0.03). Patients with displacement of ovoids in relation to the cervical os had a significantly increased risk of LR (HR, 2.50; 95% CI, 1.05-5.93; P = 0.04) and a lower DFS rate (HR, 2.28; 95% CI, 1.18-4.41; P = 0.01). Inappropriate placement of packing resulted in a lower DFS rate (HR, 2.06; 95% CI, 1.08-3.92; P = 0.03). Conclusions: Assessment of the quality of a brachytherapy implant is imperative, as proper placement has an impact on patient DFS. If feasible, inappropriate placements should be corrected before treatment initiation. Brachytherapy applicators for cervical cancer should preferably be placed and assessed by experienced practitioners.

AB - Purpose: The objective of the study was to determine the impact of brachytherapy implant quality on outcome among cervical cancer patients treated on Radiation Therapy Oncology Group prospective trials 0116 and 0128. Methods: All enrolled patients received concurrent chemoradiation followed by brachytherapy. Individual brachytherapy parameters, including the symmetry of ovoids in relation to the tandem, displacement of ovoids in relation to the cervical os, tandem bisecting the ovoids, tandem in the midpelvis, and appropriateness of packing, were scored for each implant. Multivariate Cox proportional hazards models were constructed for each parameter for local recurrence (LR), regional recurrence, distant recurrence, disease-free survival (DFS), and overall survival. Results: Records for 103 patients were analyzed. The median follow-up time was 24.5 months. Patients with unacceptable symmetry of ovoids to the tandem had a significantly higher risk of LR than patients in the acceptable group (hazard ratio [HR], 2.67; 95% confidence interval [CI], 1.11-6.45; P = 0.03). Patients with displacement of ovoids in relation to the cervical os had a significantly increased risk of LR (HR, 2.50; 95% CI, 1.05-5.93; P = 0.04) and a lower DFS rate (HR, 2.28; 95% CI, 1.18-4.41; P = 0.01). Inappropriate placement of packing resulted in a lower DFS rate (HR, 2.06; 95% CI, 1.08-3.92; P = 0.03). Conclusions: Assessment of the quality of a brachytherapy implant is imperative, as proper placement has an impact on patient DFS. If feasible, inappropriate placements should be corrected before treatment initiation. Brachytherapy applicators for cervical cancer should preferably be placed and assessed by experienced practitioners.

KW - Brachytherapy quality

KW - Cervical cancer

UR - http://www.scopus.com/inward/record.url?scp=84858163520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858163520&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e31823ae3c9

DO - 10.1097/IGC.0b013e31823ae3c9

M3 - Article

C2 - 22193645

AN - SCOPUS:84858163520

VL - 22

SP - 123

EP - 131

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -